The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Appropriate candidates for statin use in heart failure

  • Seo, Hong Seog (Cardiovascular Center, Korea University Guro Hospital)
  • Received : 2014.10.17
  • Accepted : 2014.10.22
  • Published : 2014.11.01
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Dahl CP, Gullestad L, Fevang B, et al. Increased expression of LIGHT/TNFSF14 and its receptors in experimental and clinical heart failure. Eur J Heart Fail 2008;10:352-359. https://doi.org/10.1016/j.ejheart.2008.02.010
  2. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787-1847. https://doi.org/10.1093/eurheartj/ehs104
  3. Writing Committee Members, Yancy CW, Jessup M, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013;128:e240-e327. https://doi.org/10.1161/CIR.0b013e31829e8776
  4. Laribi S, Aouba A, Nikolaou M, et al. Trends in death attributed to heart failure over the past two decades in Europe. Eur J Heart Fail 2012;14:234-239. https://doi.org/10.1093/eurjhf/hfr182
  5. Braunwald E. Heart failure. JACC Heart Fail 2013;1:1-20. https://doi.org/10.1016/j.jchf.2012.10.002
  6. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990;323:236-241. https://doi.org/10.1056/NEJM199007263230405
  7. Hambrecht R, Fiehn E, Weigl C, et al. Regular physical exercise corrects endothelial dysfunction and improves exercise capacity in patients with chronic heart failure. Circulation 1998;98:2709-2715. https://doi.org/10.1161/01.CIR.98.24.2709
  8. Tousoulis D, Charakida M, Stefanadis C. Inflammation and endothelial dysfunction as therapeutic targets in patients with heart failure. Int J Cardiol 2005;100:347-353. https://doi.org/10.1016/j.ijcard.2004.05.030
  9. Hedayat M, Mahmoudi MJ, Rose NR, Rezaei N. Proinflammatory cytokines in heart failure: double-edged swords. Heart Fail Rev 2010;15:543-562. https://doi.org/10.1007/s10741-010-9168-4
  10. El-Menyar AA. Cytokines and myocardial dysfunction: state of the art. J Card Fail 2008;14:61-74. https://doi.org/10.1016/j.cardfail.2007.09.006
  11. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT; Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003;107:3133-3140. https://doi.org/10.1161/01.CIR.0000077913.60364.D2
  12. Mann DL, McMurray JJ, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004;109:1594-1602. https://doi.org/10.1161/01.CIR.0000124490.27666.B2
  13. Yoshimura T, Kurita C, Nagao T, et al. Inhibition of tumor necrosis factor-alpha and interleukin-1-beta production by beta-adrenoceptor agonists from lipopolysaccharide- stimulated human peripheral blood mononuclear cells. Pharmacology 1997;54:144-152. https://doi.org/10.1159/000139481
  14. Feldman AM, Wagner DR, McNamara DM. AMPD1 gene mutation in congestive heart failure: new insights into the pathobiology of disease progression. Circulation 1999;99:1397-1399. https://doi.org/10.1161/01.CIR.99.11.1397
  15. Matsumori A, Shioi T, Yamada T, Matsui S, Sasayama S. Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure. Circulation 1994;89:955-958. https://doi.org/10.1161/01.CIR.89.3.955
  16. Matsumori A, Ono K, Nishio R, Nose Y, Sasayama S. Amiodarone inhibits production of tumor necrosis factor-alpha by human mononuclear cells: a possible mechanism for its effect in heart failure. Circulation 1997;96:1386-1389. https://doi.org/10.1161/01.CIR.96.5.1386
  17. Matsumori A, Ono K, Nishio R, et al. Modulation of cytokine production and protection against lethal endotoxemia by the cardiac glycoside ouabain. Circulation 1997;96:1501-1506. https://doi.org/10.1161/01.CIR.96.5.1501
  18. Ammann P, Rizzoli R, Bonjour JP, et al. Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency. J Clin Invest 1997;99:1699-1703. https://doi.org/10.1172/JCI119333
  19. Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670-1681. https://doi.org/10.1016/S0140-6736(10)61350-5
  20. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998;97:1129-1135. https://doi.org/10.1161/01.CIR.97.12.1129
  21. Tousoulis D, Antoniades C, Bosinakou E, et al. Effects of atorvastatin on reactive hyperemia and inflammatory process in patients with congestive heart failure. Atherosclerosis 2005;178:359-363. https://doi.org/10.1016/j.atherosclerosis.2004.08.037
  22. Bellosta S, Via D, Canavesi M, et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 1998;18:1671-1678. https://doi.org/10.1161/01.ATV.18.11.1671
  23. Oi S, Haneda T, Osaki J, et al. Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells. Eur J Pharmacol 1999;376:139-148. https://doi.org/10.1016/S0014-2999(99)00282-4
  24. Gastelurrutia P, Lupon J, de Antonio M, et al. Statins in heart failure: the paradox between large randomized clinical trials and real life. Mayo Clin Proc 2012;87:555-560. https://doi.org/10.1016/j.mayocp.2012.02.018
  25. Sola S, Mir MQ, Lerakis S, Tandon N, Khan BV. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol 2006;47:332-337. https://doi.org/10.1016/j.jacc.2005.06.088
  26. Mozaffarian D, Nye R, Levy WC. Statin therapy is associated with lower mortality among patients with severe heart failure. Am J Cardiol 2004;93:1124-1129. https://doi.org/10.1016/j.amjcard.2004.01.039
  27. Gissi-HF Investigators, Tavazzi L, Maggioni AP, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo- controlled trial. Lancet 2008;372:1231-1239. https://doi.org/10.1016/S0140-6736(08)61240-4
  28. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357:2248-2261. https://doi.org/10.1056/NEJMoa0706201
  29. Barrios V, Escobar C. Rosuvastatin and cardiovascular continuum when time is important. J Am Coll Cardiol 2010;55:1645-1646. https://doi.org/10.1016/j.jacc.2009.12.031
  30. Barrios V, Escobar C. Rosuvastatin along the cardiovascular continuum: from JUPITER to AURORA. Expert Rev Cardiovasc Ther 2009;7:1317-1327. https://doi.org/10.1586/erc.09.119
  31. Cleland JG, McMurray JJ, Kjekshus J, et al. Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). J Am Coll Cardiol 2009;54:1850-1859. https://doi.org/10.1016/j.jacc.2009.06.041
  32. Athyros VG, Karagiannis A, Mikhailidis DP. Statins and heart failure. J Am Coll Cardiol 2010;55:1644-1645. https://doi.org/10.1016/j.jacc.2009.11.071
  33. Khush KK, Waters DD, Bittner V, et al. Effect of highdose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study. Circulation 2007;115:576-583. https://doi.org/10.1161/CIRCULATIONAHA.106.625574
  34. Tousoulis D, Oikonomou E, Siasos G, et al. Dose-dependent effects of short term atorvastatin treatment on arterial wall properties and on indices of left ventricular remodeling in ischemic heart failure. Atherosclerosis 2013;227:367-372. https://doi.org/10.1016/j.atherosclerosis.2013.01.015
  35. Nezasa K, Higaki K, Matsumura T, et al. Liver-specific distribution of rosuvastatin in rats: comparison with pravastatin and simvastatin. Drug Metab Dispos 2002;30:1158-1163. https://doi.org/10.1124/dmd.30.11.1158
  36. Bonsu KO, Kadirvelu A, Reidpath DD. Statins in heart failure: do we need another trial? Vasc Health Risk Manag 2013;9:303-319.
  37. Lee HY, Cho HJ, Kim HY, et al. Effects of intensive versus mild lipid lowering by statins in patients with ischemic congestive heart failure: South Korean Pitavastatin Heart Failure (SAPHIRE) study. Korean J Intern Med 2014;29:754-763. https://doi.org/10.3904/kjim.2014.29.6.754
  38. Ramasubbu K, Estep J, White DL, Deswal A, Mann DL. Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. J Am Coll Cardiol 2008;51:415-426. https://doi.org/10.1016/j.jacc.2007.10.009